Genetic Polymorphysm of Cholesterol 24 S Hydroxylase in Patients With Glaucoma and AMD

NCT ID: NCT00629044

Last Updated: 2011-03-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

320 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-11-30

Study Completion Date

2011-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to assess the implicitement of the cholesterol 24 S hydroxylase gene and the 24 S hydroxycholesterol in glaucoma and in age related macular degeneration.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glaucoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SCREENING

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

G

Group Type ACTIVE_COMPARATOR

Assessing the blood level of cholesterol 24 S Hydroxylase

Intervention Type BIOLOGICAL

Comparison of venous blood level of Cholesterol 24 S hydroxylase and 24 hydroxycholesterol in patients with Glaucoma and AMD and in healthy subjects.

AMD

Group Type ACTIVE_COMPARATOR

Assessing the blood level of cholesterol 24 S hydroxylase

Intervention Type BIOLOGICAL

Comparison of venous blood level of cholesterol 24 S hydroxylase and 24 hydroxycholesterol in patients with Glaucoma, AMD end in healthy subjects

Healthy subjects

Group Type ACTIVE_COMPARATOR

assessing the blood level of cholesterol 24 S hydroxylase

Intervention Type BIOLOGICAL

Comparison of venous blood level of cholesterol 24 S hydroxylase and 24 hydroxycholesterol in patients with glaucoma, AMD and in healthy subjects

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Assessing the blood level of cholesterol 24 S Hydroxylase

Comparison of venous blood level of Cholesterol 24 S hydroxylase and 24 hydroxycholesterol in patients with Glaucoma and AMD and in healthy subjects.

Intervention Type BIOLOGICAL

Assessing the blood level of cholesterol 24 S hydroxylase

Comparison of venous blood level of cholesterol 24 S hydroxylase and 24 hydroxycholesterol in patients with Glaucoma, AMD end in healthy subjects

Intervention Type BIOLOGICAL

assessing the blood level of cholesterol 24 S hydroxylase

Comparison of venous blood level of cholesterol 24 S hydroxylase and 24 hydroxycholesterol in patients with glaucoma, AMD and in healthy subjects

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient with Glaucoma
* Patient with AMD
* Healthy patient

Exclusion Criteria

* All patients who use any treatment in order to maintain in normal value their blood cholesterol
Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre Hospitalier Universitaire Dijon

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

CHU Dijon

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Catherine Creuzot-Gracher, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

CHU Dijon

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ophthalmology Unit CHU Dijon

Dijon, Burgundy, France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

References

Explore related publications, articles, or registry entries linked to this study.

Joffre C, Souchier M, Gregoire S, Viau S, Bretillon L, Acar N, Bron AM, Creuzot-Garcher C. Differences in meibomian fatty acid composition in patients with meibomian gland dysfunction and aqueous-deficient dry eye. Br J Ophthalmol. 2008 Jan;92(1):116-9. doi: 10.1136/bjo.2007.126144.

Reference Type BACKGROUND
PMID: 18156378 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PHRC IR 2006

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

"Night Vision and Carotenoids"
NCT04741763 COMPLETED NA
Effects of Lutein in Retinitis Pigmentosa
NCT00029289 COMPLETED PHASE1/PHASE2